AR070411A1 - Forma polimorfica de n-[3-terc-butil-1-(3-cloro-4-hidroxifenil)-1h-pirazol-5-il]-n'-{2-[(3-{2-[(2-hidroxietil)sulfanil]fenil}[1,2,4]triazolo[4,3-a]piridin-6-il)sulfanil]bencil}urea, composiciones farmaceuticas que la comprenden y metodo de preparacion - Google Patents

Forma polimorfica de n-[3-terc-butil-1-(3-cloro-4-hidroxifenil)-1h-pirazol-5-il]-n'-{2-[(3-{2-[(2-hidroxietil)sulfanil]fenil}[1,2,4]triazolo[4,3-a]piridin-6-il)sulfanil]bencil}urea, composiciones farmaceuticas que la comprenden y metodo de preparacion

Info

Publication number
AR070411A1
AR070411A1 ARP090100349A ARP090100349A AR070411A1 AR 070411 A1 AR070411 A1 AR 070411A1 AR P090100349 A ARP090100349 A AR P090100349A AR P090100349 A ARP090100349 A AR P090100349A AR 070411 A1 AR070411 A1 AR 070411A1
Authority
AR
Argentina
Prior art keywords
sulfanil
triazolo
chloro
phenyl
urea
Prior art date
Application number
ARP090100349A
Other languages
English (en)
Original Assignee
Pfizer Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Ltd filed Critical Pfizer Ltd
Publication of AR070411A1 publication Critical patent/AR070411A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Neurosurgery (AREA)
  • AIDS & HIV (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)

Abstract

Esta forma polimorfa es util en el tratamiento de varios trastornos, particularmente en el tratamiento de trastornos inflamatorios tales como la enfermedad pulmonar obstructiva cronica. Reivindicacion 1: La forma polimorfa B de N-[3-terc-butil-1-(3-cloro-4-hidroxifenil)-1H-pirazol-5-il]-N'-{2-[(3-{2-[(2-hidroxietil)sulfanil]fenil}[1,2,4]triazolo[4,3-a]piridin-6-il)sulfanil]bencil}urea que muestra desplazamientos a aproximadamente 155,4, 146,2, 144,3, 116,6, 42,5 y 35,2 ppm cuando se caracteriza por 13C RMN de estado solido referenciado a un estándar externo de adamantano cristalino, fijándose la resonancia a campos altos a 29,5 ppm.
ARP090100349A 2008-02-04 2009-02-03 Forma polimorfica de n-[3-terc-butil-1-(3-cloro-4-hidroxifenil)-1h-pirazol-5-il]-n'-{2-[(3-{2-[(2-hidroxietil)sulfanil]fenil}[1,2,4]triazolo[4,3-a]piridin-6-il)sulfanil]bencil}urea, composiciones farmaceuticas que la comprenden y metodo de preparacion AR070411A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2587908P 2008-02-04 2008-02-04

Publications (1)

Publication Number Publication Date
AR070411A1 true AR070411A1 (es) 2010-04-07

Family

ID=40911989

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090100349A AR070411A1 (es) 2008-02-04 2009-02-03 Forma polimorfica de n-[3-terc-butil-1-(3-cloro-4-hidroxifenil)-1h-pirazol-5-il]-n'-{2-[(3-{2-[(2-hidroxietil)sulfanil]fenil}[1,2,4]triazolo[4,3-a]piridin-6-il)sulfanil]bencil}urea, composiciones farmaceuticas que la comprenden y metodo de preparacion

Country Status (23)

Country Link
US (1) US8222273B2 (es)
EP (1) EP2303267B1 (es)
JP (1) JP5344942B2 (es)
KR (2) KR101422318B1 (es)
CN (1) CN101939320B (es)
AR (1) AR070411A1 (es)
AU (1) AU2009211072B2 (es)
BR (1) BRPI0907463A2 (es)
CA (1) CA2712574C (es)
CY (1) CY1114389T1 (es)
DK (1) DK2303267T3 (es)
ES (1) ES2423991T3 (es)
HK (1) HK1147481A1 (es)
IL (1) IL206948A (es)
MX (1) MX2010008535A (es)
NZ (1) NZ587094A (es)
PL (1) PL2303267T3 (es)
PT (1) PT2303267E (es)
RU (1) RU2448966C1 (es)
SI (1) SI2303267T1 (es)
TW (1) TWI391391B (es)
WO (1) WO2009098612A2 (es)
ZA (1) ZA201005137B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0905955D0 (en) 2009-04-06 2009-05-20 Respivert Ltd Novel compounds
CN103200938B (zh) 2010-08-30 2018-07-31 普马特里克斯营业公司 干燥粉末配方及用于治疗肺部疾病的方法
EP2448571B1 (en) 2010-08-30 2013-06-12 Pulmatrix, Inc. Respirably dry powder comprising calcium lactate, sodium chloride and leucine
ES2899621T3 (es) 2010-09-29 2022-03-14 Pulmatrix Operating Co Inc Polvos secos catiónicos que comprenden sal de magnesio
US20140336159A1 (en) 2011-10-07 2014-11-13 Pulmatrix, Inc. Methods for treating and diagnosing respiratory tract infections
US9458154B2 (en) 2011-12-09 2016-10-04 Chiesi Farmaceutici S.P.A. Kinase inhibitors
CN105646484A (zh) * 2016-03-01 2016-06-08 孙霖 晶型b及制备方法
CN105693716A (zh) * 2016-03-01 2016-06-22 孙霖 晶型a及制备方法
GB201721793D0 (en) 2017-12-22 2018-02-07 Hvivo Services Ltd Methods and compunds for the treatment or prevention of hypercytokinemia and severe influenza

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP990182A2 (en) 1998-06-11 2000-02-29 Du Pont Pharm Co Crystalline efavirenz
CA2351727C (en) * 1998-11-20 2008-09-23 Mitsubishi Chemical Corporation Crystals of 5-[{6-(2-fluorobenzyl)oxy-2-naphthyl}methyl]-2,4-thiazolidinedione
US7847112B2 (en) 2004-07-16 2010-12-07 Health Science Funding, LLC Polymorphs of atovaquone and process of preparation thereof
GB0418015D0 (en) * 2004-08-12 2004-09-15 Pfizer Ltd New compounds
AU2005273612B2 (en) * 2004-08-12 2010-10-14 Pfizer Inc. Triazolopyridinylsulfanyl derivatives as p38 map kinase inhibitors

Also Published As

Publication number Publication date
AU2009211072A1 (en) 2009-08-13
CA2712574C (en) 2014-01-07
CY1114389T1 (el) 2016-08-31
IL206948A (en) 2014-12-31
RU2448966C1 (ru) 2012-04-27
JP2009185028A (ja) 2009-08-20
PL2303267T3 (pl) 2013-11-29
EP2303267B1 (en) 2013-07-03
MX2010008535A (es) 2010-08-30
CN101939320A (zh) 2011-01-05
ES2423991T3 (es) 2013-09-26
DK2303267T3 (da) 2013-09-02
EP2303267A2 (en) 2011-04-06
US8222273B2 (en) 2012-07-17
KR20130087048A (ko) 2013-08-05
KR20100108409A (ko) 2010-10-06
JP5344942B2 (ja) 2013-11-20
NZ587094A (en) 2011-07-29
CA2712574A1 (en) 2009-08-13
PT2303267E (pt) 2013-08-05
KR101422318B1 (ko) 2014-07-22
WO2009098612A2 (en) 2009-08-13
US20110003848A1 (en) 2011-01-06
IL206948A0 (en) 2010-12-30
TW200944524A (en) 2009-11-01
RU2010132639A (ru) 2012-02-10
SI2303267T1 (sl) 2013-09-30
WO2009098612A3 (en) 2009-10-08
ZA201005137B (en) 2011-03-30
TWI391391B (zh) 2013-04-01
AU2009211072B2 (en) 2014-01-23
BRPI0907463A2 (pt) 2019-09-24
CN101939320B (zh) 2013-11-20
HK1147481A1 (en) 2011-08-12

Similar Documents

Publication Publication Date Title
AR070411A1 (es) Forma polimorfica de n-[3-terc-butil-1-(3-cloro-4-hidroxifenil)-1h-pirazol-5-il]-n'-{2-[(3-{2-[(2-hidroxietil)sulfanil]fenil}[1,2,4]triazolo[4,3-a]piridin-6-il)sulfanil]bencil}urea, composiciones farmaceuticas que la comprenden y metodo de preparacion
DOP2006000210A (es) Compuestos de pirimidina amida como inhibidores de pgds
NI201100006A (es) Derivados de triazol útiles para el tratamiento de enfermedades.
EA201170251A1 (ru) ЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ 1,2,3,4-ТЕТРАГИДРОЦИКЛОПЕНТА[b]ИНДОЛ-3-ИЛ)УКСУСНОЙ КИСЛОТЫ, ПРИМЕНИМЫЕ В ЛЕЧЕНИИ АУТОИММУННЫХ И ВОСПАЛИТЕЛЬНЫХ РАССТРОЙСТВ
MX2011008501A (es) Compuestos heterociclicos fusionados que contienen nitrogeno y su uso como inhibidores de la produccion de beta-amiloide.
ECSP14013221A (es) Fenil-3-aza-biciclo [3.1.0] hex-3-il-metanonas y su uso como medicamento.
MX346101B (es) Sonda de formacion de imagen de tau.
MX347706B (es) Derivados de triazol y su uso para trastornos neurologicos.
ATE531711T1 (de) Für die behandlung von autoimmunerkrankungen und entzündlichen erkrankungen geeignete tetrahydrocyclopentaäbüindol-3- ylcarbonsäurederivate
ATE538100T1 (de) Aminotetrahydroindazoloessigsäuren
BR112012020557A8 (pt) formas cristalinas de 4-{[9-cloro-7-(2-flúor-6-metoifenil)-5h-pirimido[5,4-d][2]benzazepin-2-il]amino}-2-metoxibenzoato de sódio
NO20083708L (no) 4-Fenyl-tiazol-5-karboksylsyre og 4-fenyl-tiazol-5-karboksylmider som PLK1-inhibitorer
WO2012059442A3 (en) Neurotrypsin inhibitors
WO2011089396A3 (en) Pyruvamide compounds as inhibitors of dust mite group 1 peptidase allergen
WO2018071315A3 (en) Piperidine derivatives as liver x receptor beta agonists, compositions, and their use
UY37987A (es) Procedimiento para la preparación de (3s)-3-(4-cloro-3-{[(2s,3r)-2-(4-clorofenil)-4,4,4-trifluor-3- metilbutanoil]amino}fenil)-3-ácido ciclopropilpropanoico y su forma cristalina para uso como principio activo farmacéutico.
NZ592740A (en) Carbamate derivatives of alkyl-heterocycles, preparation thereof and therapeutic use thereof
FR2961803B1 (fr) Compositions acides pour l'elimination des oxalates
CO6640307A2 (es) Derivados de flufenoxina para el tratamiento y la prevención de patologías amiloides
TH109283B (th) อัลคิลไซโคลเฮกซิลอีเธอร์ ของไดไฮโดรเตตระเอซาเบนโซเอซูลีน
Frydman This is a long period by the rapidly-changing standards of contemporary Science; a maturity which might challenge the continued rate of progress of any field--and accordingly the fate of a journal like JMR
TH109167B (th) อิมิดาโซไพริดาซีนที่ถูกแทนที่เพื่อเป็นสารยับยั้งไลปิดไคเนส
TH134115B (th) การใช้สารในกลุ่มอิมิดาโซ [1,2-ซี]ไพริมิดีนที่มีการแทนที่ที่ตำแหน่งที่ 5,7 เป็นสารยับยั้ง jak ไคเนส
TH109283A (th) อัลคิลไซโคลเฮกซิลอีเธอร์ ของไดไฮโดรเตตระเอซาเบนโซเอซูลีน
TH78318B (th) ยูเรียและคาร์บาเมทซึ่งถูกแทนที่ที่เป็นประโยชน์ในการรักษาโรคอัลไซเมอร์

Legal Events

Date Code Title Description
FB Suspension of granting procedure